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Isoform-Specific Dominant-Negative Effects Associated
with hERG1 G628S Mutation in Long QT Syndrome
Matthew R. Stump, Qiuming Gong, Zhengfeng Zhou*
Division of Cardiovascular Medicine, Department of Medicine, Oregon Health & Science University, Portland, Oregon, United States of America

Abstract
Background: Mutations in the human ether-a-go-go-related gene 1 (hERG1) cause type 2 long QT syndrome (LQT2). The
hERG1 gene encodes a K+ channel with properties similar to the rapidly activating delayed rectifying K+ current in the heart.
Several hERG1 isoforms with unique structural and functional properties have been identified. To date, the pathogenic
mechanisms of LQT2 mutations have been predominantly described in the context of the hERG1a isoform. In the present
study, we investigated the functional consequences of the LQT2 mutation G628S in the hERG1b and hERG1aUSO isoforms.
Methods: A double-stable, mammalian expression system was developed to characterize isoform-specific dominantnegative effects of G628S-containing channels when co-expressed at equivalent levels with wild-type hERG1a. Western blot
and co-immunoprecipitation studies were performed to study the trafficking and co-assembly of wild-type and mutant
hERG1 isoforms. Patch-clamp electrophysiology was performed to characterize hERG1 channel function and the isoformspecific dominant-negative effects associated with the G628S mutation.
Conclusions: The non-functional hERG1a-G628S and hERG1b-G628S channels co-assembled with wild-type hERG1a and
dominantly suppressed hERG1 current. In contrast, G628S-induced dominant-negative effects were absent in the context of
the hERG1aUSO isoform. hERG1aUSO-G628S channels did not appreciably associate with hERG1a and did not significantly
suppress hERG1 current when co-expressed at equivalent ratios or at ratios that approximate those found in cardiac tissue.
These results suggest that the dominant-negative effects of LQT2 mutations may primarily occur in the context of the
hERG1a and hERG1b isoforms.
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trafficking. The hERG1 gene has an alternate transcription start
site within intron 5 that generates a transcript encoding the
hERG1b isoform [12,13,14]. The 376 N-terminal residues of
hERG1a channels are replaced by 36 unique residues in hERG1b
resulting in channels that exhibit accelerated rates of channel
deactivation. Recent studies have shown that hERG1b coassembles with hERG1a and it was suggested that the heteromeric
channels underlie native ventricular IKr [15]. A third hERG1
isoform, hERG1aUSO, arises from the inefficient splicing of intron
9 resulting in premature termination and polyadenylation within
intron 9 [16]. The 359 C-terminal residues of hERG1a are
replaced by 88 unique residues in hERG1aUSO channels. In
contrast to hERG1a and hERG1b, hERG1aUSO is trafficking
defective and does not generate hERG1 current when expressed in
mammalian cells [17,18]. hERG1aUSO has been shown to coassemble with hERG1a, interfering with the trafficking of the
functional isoform, when over-expressed relative to hERG1a in
heterologous systems [18].
The majority of LQT2 mutations occur within coding regions
common to hERG1a, hERG1b, and hERG1aUSO, however, the
functional consequences of these mutations, including G628S,
have been primarily characterized in hERG1a. hERG1a-G628S

Introduction
Long QT syndrome (LQTS) is a cardiac disorder characterized
by QT prolongation and an increased risk of severe ventricular
arrhythmias that can result in sudden death [1,2]. Mutations in the
human ether-go-go-related gene 1 (hERG1) result in LQTS type 2
(LQT2) and account for 25 to 40% of genotyped cases of LQTS
[3,4,5]. To date, over 500 LQT2 mutations have been identified.
The hERG1 gene encodes the pore-forming subunit of the rapidly
activating delayed rectifier K+ channel (IKr) in the heart, which
contributes to the repolarization of the cardiac action potential
[6,7]. Most LQT2 mutations are loss of function mutations that
result in decreased hERG1 current levels and several mutations
are known to dominantly suppress wild-type hERG1 current [8,9].
Several hERG1 isoforms have been identified in the heart and
are known to modulate IKr. The first cloned hERG1 isoform,
hERG1a, contains 1159 amino acids and represents the full-length
hERG1 channel protein [10]. hERG1a channels exhibit voltagedependent activation and undergo inactivation at positive
depolarizing potentials [6,7,11]. The N-terminus of hERG1a
plays an important role in channel deactivation, while several
regions in the C-terminus contribute to channel assembly and
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17.561.2 pA/pF (n = 21) and 3.060.3 pA/pF (n = 6). The
decrease in the tail current amplitude of hERG1b is consistent
with previous reports and is caused by rapid channel deactivation
and decreased trafficking of the hERG1b isoform to the cellsurface [19,20].
The trafficking properties of hERG1 isoforms were determined
by western blot analysis using anti-Flag antibody (Fig. 4A). Wildtype and mutant hERG1a channels were expressed as the
immature and mature channel proteins as described in Fig. 2A.
Wild-type and mutant hERG1b channels were expressed as the
immature (90 kDa) and the mature (105 kDa) channel proteins. As
has been previously shown, hERG1b protein was primarily
expressed as the immature band indicating that hERG1b does
not traffic as efficiently as hERG1a channels. The low trafficking
efficiency of hERG1b channel has been attributed to the presence
of an endoplasmic reticulum retention signal found in the unique
N-terminus of the isoform [20]. The G628S mutation does not
appear to alter the trafficking properties of the wild-type hERG1a
and hERG1b channels. The trafficking efficiency of wild-type and
mutant hERG1a and hERG1b was defined as the ratio of the
upper band to the total hERG1 protein. As shown in Fig. 4B, the
G628S mutation does not significantly alter the trafficking
efficiency of hERG1a or hERG1b (n = 3, P.0.05). Wild-type
and mutant hERG1aUSO were expressed as the immature channel
protein at 100 kDa indicating that the isoform is trafficking
deficient [18].

channels have been found to be non-functional and to dominantly
suppress wild-type hERG1 current [8]. In the present study we
characterized the functional properties of the G628S mutation in
the context of hERG1b and hERG1aUSO isoforms. We developed
a double-stable, mammalian expression system using a recombinase-mediated recombination strategy to study the isoform-specific
dominant-negative effects of the G628S mutation. We found that
the assembly of hERG1a with hERG1a-G628S or hERG1bG628S resulted in the dominant suppression of hERG1 current. In
contrast, hERG1aUSO-G628S did not readily associate with
hERG1a, and consequently, did not suppress hERG1 current
when co-expressed at a 1:1 ratio or at ratios that approximate
those found in cardiac tissue. These results suggest that pathogenic
consequences of LQT2 mutations may primarily occur in
hERG1a and hERG1b.

Results
Design of the Flp-Cre expression system
To characterize the functional properties and the dominantnegative effects of the G628S mutation in the hERG1a, hERG1b
and hERG1aUSO isoforms, we developed a novel, double-stable,
mammalian expression system (described in detail in the Materials
and Methods, Fig. 1). Briefly, we stably introduced a loxP2272/
loxP recombination cassette into Flp-In-293 cells using the pCRE/
GFP target vector. To confirm that the loxP2272/loxP cassette had
integrated at a single genomic locus we performed quantitative
real-time PCR using primers specific to the zeocin gene, a
component of the FRT cassette and to GFP, a component of the
loxP2272/loxP cassette. The averaged GFP/zeocin ratio was
1.0260.04 (n = 3). Since Flp-In-293 cells contain a single copy
of the FRT site, the real-time PCR results indicate that Flp-Cre
cells contain a single copy of the loxP2272/loxP site.
We performed western blot and patch-clamp analyses to
compare the expression of HA-tagged hERG1a channels stably
integrated at the FRT or the loxP2272/loxP site (Fig. 2). hERG1a
channel proteins integrated at both sites were expressed as the
core-glycosylated, immature form (135 kDa) and the fully-glycosylated, mature form (155 kDa) (Fig. 2A). Quantitative densitometry revealed that the ratio of hERG1a expressed from the
loxP2272/loxP relative to the FRT site was 1.1160.18. Functional
studies revealed similar levels of hERG1a current recorded from
the two cell lines (Fig. 2B). The averaged peak tail current
amplitudes of hERG1a expressed from the FRT and loxP2272/
loxP sites were 21.361.9 pA/pF (n = 8) and 23.662.6 (n = 10,
P.0.05), respectively. These results indicated that the Flp-Cre
system would permit the characterization of LQT2-induced
dominant-negative effects at a 1:1 expression ratio when cotransfected with wild-type and mutant hERG1 channel constructs.

Isoform-specific dominant-negative effects
To characterize the dominant-negative effects of the G628S
mutation we generated cell lines co-expressing wild-type hERG1a
and mutant hERG1 isoforms at a 1:1 ratio. Double-stable Flp-Cre
cell lines were generated with hERG1a-HA at the FRT site and
empty vector, hERG1a-G628S-Flag, hERG1b-G628S-Flag, or
hERG1aUSO-G628S-Flag at the loxP2272/loxP site. The dominant-negative suppression of hERG1 current by the mutant
hERG1a and hERGb channels is clearly shown in Fig. 5. The
average peak tail current density recorded from cells co-transfected
with hERG1a + vector was 25.061.1 pA/pF (n = 14). When
hERG1a was co-expressed with hERG1a-G628S or hERG1bG628S we observed a significant decrease in hERG1 current as
compared to hERG1a + vector control (3.960.7 pA/pF, n = 20
and 3.760.7 pA/pF, n = 7, respectively, P,0.05). In contrast,
current recorded from cells expressing hERG1a + hERG1aUSOG628S cells was not significantly different from the control
(24.562.5 pA/pF, n = 11, P.0.05). These results strongly suggest
that mutant hERG1a and hERG1b may be primarily responsible
for the pathological consequences of LQT2 mutations.

Isoform-specific assembly of hERG1 isoforms
To determine the underlying mechanism of the isoform-specific
dominant-negative effects of the G628S mutation we determined
whether hERG1a co-assembled with the wild-type and mutant
hERG1 isoforms (Fig. 6). The expression of the hERG1 channels
from the double-stable cell lines used in Fig. 5 was confirmed by
western blot analysis. Co-assembly of the differentially-tagged
hERG1 isoforms was determined by immunoprecipitating
hERG1a-HA with the anti-HA antibody and detecting Flagtagged hERG1 channels by western blot with the anti-Flag
antibody. Western blot analysis with the anti-HA antibody
revealed that hERG1a was efficiently immunoprecipitated. As
expected, hERG1a-G628S and hERG1b-G628S readily associated with both mature and immature hERG1a channels. The coassembly of the G628S-containing 1a and 1b isoforms with wildtype hERG1a gives rise to the dominant-negative suppression of

Functional properties of hERG1 isoforms containing the
LQT2 mutation G628S
To characterize the functional properties of the G628S
mutation we generated stable Flp-Cre cell lines expressing Flagtagged wild-type or mutant hERG1 isoforms from the loxP2272/
loxP site. Representative current traces of wild-type and mutant
hERG1 isoforms are shown in Fig. 3A. hERG1a and hERG1b
channels exhibited voltage-dependent activation and inward
rectification at more positive depolarizing potentials. hERG1
current was not detected in cells transfected with hERG1aUSO or
with mutant hERG1a, hERG1b or hERG1aUSO isoforms. The
current-voltage plot shown in Fig. 3B compares the average peak
tail current density of the wild-type hERG1 isoforms. The
maximum tail densities of hERG1a and hERG1b channels were
PLoS ONE | www.plosone.org
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Figure 1. Schematic illustrating the generation of the double-stable Flp-Cre cell line. (A) The pCRE/GFP target vector was designed to
introduce the loxP2272/loxP recombination cassette into Flp-In-293 cells. The recombination cassette is comprised of incompatible loxP2272 and loxP
sites flanking the puromycin resistance gene (puroR) and green fluorescent protein (GFP). The cytomegalovirus promoter (pCMV) drives the
expression of GFP. The phosphoglycerate kinase promoter (pPGK) was inserted upstream of the loxP2272 site to control the expression of the puroR.
(B) The pUC18/loxP expression vector was designed to stably integrate the gene of interest (GOI) at the loxP2272/loxP cassette of Flp-Cre cells using a
Cre recombinase-mediated cassette exchange approach. The loxP2272/loxP cassette of the expression vector contains the neomycin resistance gene
(neoR) and the CMV promoter which controls the expression of the GOI. The promoter for neoR expression, pPGK, is only provided following
recombination at the loxP2272/loxP site within Flp-Cre cells. (C) Flp recombinase-mediated recombination is used to introduce the gene of interest at
the FRT target site. The FRT target site is comprised of the zeocin resistance gene (zeoR) under the control of the simian virus 40 early promoter
(pSV40). HA-tagged hERG1a (1a-HA) was stably introduced by co-transfection with the pcDNA5/FRT expression vector and a Flp recombinase
expression vector according to the Flp-In System protocol (Invitrogen). Additional components of the pcDNA5/FRT expression vector include the
hygromycin resistance gene (hygR), pUC ori, and the ampicillin resistance gene (ampR). (D) Cre recombinase-mediated cassette exchange is used to
introduce the gene of interest at the loxP2272/loxP site. Flag-tagged hERG1 (1-Flag) constructs were stably integrated into the Flp-Cre hERG1-HA
stable cell line by co-transfection of the pUC18/loxP expression vector and a Cre recombinase expression vector. (E) The double-stable Flp-Cre cell line
contains a single copy of the HA-tagged hERG1a gene and the Flag-tagged hERG1 gene.
doi:10.1371/journal.pone.0042552.g001

the cell processes, an indicative of trafficking deficiency. These
results are consistent with the western blot, patch clamp and coimmunoprecipitation studies and support the conclusion that
hERG1aUSO-G628S is trafficking defective and does not readily
associate with hERG1a.
Previous quantitative real-time PCR and RNase protection
assay studies have shown that hERG1aUSO mRNA is present at
approximately twice the level of hERG1a in the heart [16,17]. We
wondered whether hERG1aUSO exerted a dominant-negative
effect on hERG1 current when co-expressed with wild-type
hERG1a at ratios that approximate those found in the heart. To
modify the relative expression of hERG1 isoform in the Flp-Cre
cell line we replaced the strong CMV promoter of the pcDNA5/
FRT expression vector with the weaker SV40 promoter, effectively
decreasing the level of the hERG1a-HA expressed from the FRT
site following the stable transfection of Flp-Cre cells. We generated
Flp-Cre cell lines expressing hERG1a-HA from the SV40
promoter at the FRT site and empty vector, hERG1a-G628SFlag or hERG1aUSO-628-Flag from the CMV promoter at the
loxP2272/loxP site. The Flp-Cre cell line containing hERG1a-HA

hERG1 current. In contrast, wild-type and mutant hERG1aUSO
proteins showed minimal association with hERG1a as evidenced
by the presence of faint bands corresponding to the hERG1aUSO
channel that were observed only upon over-exposure. To test
whether the association between hERG1a and hERG1aUSO was
destabilized by the detergent used in the immunoprecipitation
buffer we repeated the immunoprecipitation experiments using
buffer in which the Triton X-100 detergent was replaced with the
NP40 detergent (Fig. S1). Similar faint bands were observed upon
over-exposure of the blot. These results support the conclusion
that the association between hERG1a and hERG1aUSO is
significantly weaker than the association of 1a/1a and 1a/1b
isoforms.
To further characterize trafficking of the mutant hERG1aUSO
channels we performed immunofluorescence studies using Flp-Cre
cells stably expressing HA-tagged hERG1a and Flag-tagged
hERG1a-G628S or Flag-tagged hERG1aUSO-G628S channels
(Fig. S2). Wild-type and mutant hERG1a exhibited a diffuse
staining pattern visible throughout the cell including the cell
processes. In contrast, hERG1aUSO-G628S was not observed in
PLoS ONE | www.plosone.org
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association between the wild-type channel and the mutant
isoforms we immunoprecipitated hERG1a-HA with the anti-HA
antibody and performed western blot analysis with the anti-Flag
and the anti-HA antibody (Fig. 7B). As expected, hERG1a-G628S
was found to readily associate with wild-type hERG1a channels.
In contrast, hERG1aUSO-G628S did not co-assemble with
hERG1a at levels approximating cardiac hERG1a:hERG1aUSO
ratios.
We performed patch-clamp analysis to test whether hERG1
current was dominantly suppressed by the increased relative
expression of hERG1aUSO-G628S (Fig. 8). Flp-Cre cell lines coexpressing hERG1a from the SV40 promoter and empty vector or
hERG1a-G628S from the CMV promoter were used as controls.
Representative current trances are shown in Fig. 8A. The peak tail
current density from cells expressing hERG1a + vector was
9.261.5 pA/pF (n = 12), approximately 63% less than the current
generated from Flp-Cre cells expressing hERG1a from the strong
CMV promoter (Fig. 5). The peak tail current recorded from cells
expressing hERG1a + hERG1a-G628S was 0.560.4 pA/pF
(n = 12, P,0.05 compared to hERG1a/vector control) indicating
the near complete loss of hERG1 current (Fig. 8B). The coexpression of hERG1a and hERG1aUSO, however, did not
significantly alter hERG1 current levels compared to the control
(8.360.8 pA/pF, n = 11, P.0.05) (Fig. 8B). These results suggest
that mutant hERG1aUSO channels may not have a significant role
in the pathogenesis of LQT2.

Discussion
In this study we analyzed the isoform-specific effects of the
G628S LQT2 mutation on the function, trafficking, assembly and
dominant-negative properties of the hERG1a, hERG1b and
hERG1aUSO isoforms. While the mutation did not alter the
trafficking properties of hERG1a and hERG1b, it completely
disrupted the function of the both isoforms. Wild-type and mutant
hERG1aUSO channels were trafficking deficient and non-functional. The G628S-induced dominant-negative effects were
observed in the context of hERG1a and hERG1b but not
hERG1aUSO when co-expressed with wild-type hERG1a at
equivalent ratios or at ratios that approximate those found in
the heart. The Flp-Cre system allowed the equivalent stable
expression of two hERG1 isoforms. This system represents an
advantage over the co-expression of two genes from a single
promoter using IRES-containing bicistronic vectors which often
exhibit decreased expression of the second, IRES-dependent gene
[21,22].
The G628S mutation was one of the earliest loss-of-function
LQT2 mutations to be characterized and shown to dominantly
suppress the function of hERG1a when expressed in Xenopus
oocytes [8]. Because of the mutation’s severe pathogenic
phenotype, it has since been widely used in the characterization
of the function and dysfunction of hERG1a channels and IKr
[23,24,25]. Our results clearly show that hERG1b-G628S
channels are dysfunctional and confer significant dominantnegative effects, comparable to those observed in hERG1aG628S. hERG1a-G628S and hERG1b-G628S were both shown
to decrease hERG1 current by 85% when co-expressed with
hERG1a at a 1:1 ratio. hERG1a and hERG1b differ structurally
in the length and the composition of the N-terminus with hERG1b
lacking several regions that contribute to the regulation of channel
deactivation. These regions include the Per, Arnt, and Sim (PAS)
domain that orients the N-terminus into close proximity to the S4–
S5 linker and the cyclic nucleotide binding domain [26,27,28].
The absence of these N-terminal regulatory domains resulted in

Figure 2. Biochemical and functional analysis of hERG1a
expressed from the FRT and loxP2272/loxP sites in Flp-Cre cells.
(A) Flp-Cre cells stably expressing HA-tagged hERG1a (1a) from the FRT
or the loxP2272/loxP sites were detected by western blot with the antiHA antibody. Tubulin was used as a loading control. Results shown are
representative of three independent experiments. (B) Representative
current traces recorded from cells stably expressing hERG1a from the
FRT and the loxP2272/loxP sites. The channels were activated by
depolarizing steps between 270 and 60 mV from a holding potential of
280 mV and tail current was recorded upon repolarization to 250 mV.
doi:10.1371/journal.pone.0042552.g002

expressed from the CMV promoter at the FRT site and empty
vector at the loxP2272/loxP site (described in Fig. 5) was used a
control. Wild-type hERG1a channels were detected by western
blot using the anti-HA antibody (Fig. 7A, top panel). The relative
amounts of hERG1a channel proteins expressed from the two
promoters are clearly shown. The hERG1a expressed from the
SV40 promoter was found to be 3967% of that expressed from
the CMV promoter. Re-probing the membrane with the anti-Flag
antibody revealed the presence of hERG1a-G628S and hERG1aUSO-G628S channel proteins expressed from the CMV
promoter (Fig. 7A middle panel).To characterize the physical
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Figure 3. Functional analysis of wild-type and mutant hERG1 isoforms. (A) Representative currents recorded from Flp-Cre cells stably
expressing Flag-tagged wild-type or G628S-mutant (Mut) hERG1a (1a), hERG1b (1b), and hERG1aUSO (1aUSO) from the loxP2272/loxP site. (B) Currentvoltage plot of the peak tail current amplitude measured at 250 mV following depolarizing voltages from 270 to 60 mV recorded from 1a (circles,
n = 21), 1b (diamonds, n = 6) and 1aUSO (squares, n = 6) channels. The voltage-clamp protocol is given in the legend of Fig. 2.
doi:10.1371/journal.pone.0042552.g003

The hERG1aUSO-G628S isoform, however, did not dominantly
suppress hERG1a current. The isoform-specific effects of the
G628S mutation are likely due to the structural and functional
properties of the different isoforms. The structural difference
between hERG1aUSO and hERG1a or hERG1b is the length and
the composition of the C-terminus. hERG1aUSO lacks the 359 Cterminal residues of hERG1a/1b which are replaced by 88
unique, presumably unstructured residues. This is due to
alternative polyadenylation within intron 9 [16]. The C-terminal
region of hERG1a/1b contains several domains that are
important in hERG channel trafficking, assembly and function.
The cyclic nucleotide binding domain of hERG1 plays an
important role in the trafficking of hERG1 channels to the cell
surface as LQT2 mutations occurring within this domain are
known to disrupt channel trafficking [29,30,31,32]. The truncation of the C-terminus deletes two additional C-terminal domains
that contribute to hERG1a assembly. The region from residues
1018 to 1122 was reported to be necessary for the recapitulation of
hERG1 current in C-terminally truncated channels [17], and a
small, ‘‘tetramerizing coiled coil’’ domain (residues 1037 to 1074)
was also proposed to mediate channel assembly [33]. The absence
of all three of these domains likely underlies the dysfunction,
defective trafficking, and impaired assembly of hERG1aUSO in the
present studies. The absence of the full-length C-terminus in the
hERG1aUSO-G628S channels prevents the trafficking of the
mutant channel and limits the association between the mutant
channel and the full-length hERG1a channel, precluding the
dominant-negative effects.
In our co-immunoprecipitation experiments, a small fraction of
hERG1aUSO was found to associate with hERG1a (Fig. 6 and Fig.
S1) indicating that the absence of the hERG1a C-terminus does
not completely preclude channel assembly. The heteromeric
assembly of hERG1a and hERG1aUSO under conditions in which
the trafficking defective isoform is strongly over-expressed has
been shown to regulate the surface expression of hERG1a [18]. A
similar effect has been observed in voltage-gated Shaker B
channels that lack the T1 tetramerization domain wherein
removing T1 severely impairs assembly efficiency and increasing
subunit concentration can partially overcome this assembly defect
[34]. It is likely that the co-assembly of hERG1a and hERG1aUSO
is partially driven by the over-expression of the hERG1aUSO
subunit. The co-expression of differentially tagged hERG1

the accelerated deactivation rates observed in Fig. 3. While the
relative expression level of hERG1b mRNA comprises less than
20% of the total hERG1 mRNA in the heart, studies in Xenopus
oocytes have shown that these levels are sufficient to modulate
hERG1 deactivation rates [19]. The dominant-negative effects of
hERG1b-G628S shown in the present study underscore the
pathological significance of LQT2 mutations in the hERG1b
isoform.

Figure 4. Western blot analysis of wild-type and mutant hERG1
isoforms. (A) Proteins from Flp-Cre cells stably transfected with Flagtagged wild-type (WT) or G628S-mutant (Mut) hERG1a (1a), hERG1b (1b)
and hERG1aUSO (1aUSO) isoforms from the loxP2272/loxP site were
detected with the anti-Flag antibody. Mature, fully-glycosylated hERG1a
and hERG1b channels are 155 kDa and 105 kDa, respectively; immature,
core-glycosylated hERG1a, hERG1b, and hERG1aUSO channels are
135 kDa, 90 kDa, and 100 kDa, respectively. Neomycin phosphotransferase II (NPT II) was detected by a polyclonal anti-NPT II antibody. (B)
The trafficking efficiency is plotted as the percentage of the normalized
upper, mature band to the total normalized hERG1 protein. The data
are plotted as mean 6 SEM. Results shown are representative of three
independent experiments.
doi:10.1371/journal.pone.0042552.g004
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Figure 5. Isoform-specific dominant-negative effects. (A) Representative current traces from Flp-Cre cells stably co-expressing hERG1a-HA (1a)
with G628S-mutant hERG1a-Flag (1a-Mut), hERG1b-Flag (1b-Mut), or hERG1aUSO-Flag (1aUSO-Mut). Flp-Cre cells co-transfected hERG1a and empty
vector were used as a control. hERG1 current was recorded using the protocol described in the Fig. 2 legend. (B) Averaged hERG1 tail current
amplitude measured at 250 mV following depolarizing voltages to 30 mV. The number of cells is shown in parentheses.
doi:10.1371/journal.pone.0042552.g005

isoforms using the Flp-Cre system allowed us to directly compare
the assembly of hERG1a and hERG1aUSO to homomeric
hERG1a and heteromeric hERG1a and hERGb channels. The
present results suggest that the assembly deficient hERG1aUSO

isoform exerts minimal effects on the trafficking and function of
hERG1a when co-expressed at ratios that approximate those
found in cardiac tissue. An alternative mechanism of hERG1a
current regulation by the mutually exclusive generation of either
hERG1a or hERG1aUSO from the alternative processing of
hERG1a pre-mRNA has recently been described [16].
In summary, our study highlights the differential disease-causing
effects of LQT2 mutations in the three major hERG1 isoforms.
The absence of hERG1aUSO dominant-negative effects is
presumed to be due to trafficking deficiencies and the minimal
co-assembly of between the hERG1aUSO and hERG1a. Although
hERG1aUSO represents the hERG1 isoform with the highest
expression level in the heart it appears that congenital LQT2 may
primarily be caused by mutant hERG1a and hERG1b channels.
The Flp-Cre expression system, developed in these studies, may
prove to be useful in future studies of hERG1 channel function
and dysfunction. Furthermore, the stable expression of two genes
at an equivalent molar ratio using the Flp-Cre system may have
broad applications in the characterization of protein function and
dysfunction as well as in the analyses of protein-protein
interactions.

Materials and Methods
hERG isoform cDNA constructs
hERG1b was cloned from the human heart Marathon-Ready
cDNA (Clontech, Mountain View, CA) by PCR using 59-GGG
GAT CCG GCA GGC TGC AGG GAG CCA A-39 (hERG1b
forward) and 59-GCC GAC ACG TTG CCG AAG ATG CTA-39
(hERG1b reverse) primers. The PCR fragment was sequenced and
subcloned into the backbone of hERG1a at BamHI and BglII sites
to obtain the full-length hERG1b cDNA. The generation of
hERG1aUSO cDNA has been described [16]. The generation of
C-terminally Flag- and hemagglutinin (HA)-tagged hERG1 cDNA
constructs have been described [32,35]. The G628S mutation was
generated by the Gene-Editor mutagenesis system (Promega,
Madison, WI) and confirmed by sequencing.

Figure 6. Co-assembly of hERG1 isoforms. Proteins from Flp-Cre
cells co-expressing HA-tagged hERG1a (1a) with Flag-tagged wild-type
(WT) or mutant (Mut) 1a, hERG1b (1b) or hERG1aUSO (1aUSO) channels
were detected by western blot with the anti-HA and the anti-Flag
antibody (upper two panels). Co-assembly of hERG1 isoforms was
determined by immunoprecipitation with the anti-HA antibody and
detection with the anti-Flag and the anti-HA antibody (lower three
panels). Results shown are representative of three independent
experiments.
doi:10.1371/journal.pone.0042552.g006
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Design of the double-stable Flp-Cre cell line
To develop a double-stable mammalian expression system, we
designed a target vector to introduce a loxP2272/loxP recombination cassette into the mammalian cell line Flp-In-293 (Invitrogen,
Carlsbad, CA). Flp-In-293 cells are derived from the HEK-293
cell line by the integration of the Flp recombination target (FRT)
site at a single genomic locus. The pCRE/GFP target vector was
6
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Figure 8. Functional analysis of hERG1a co-expressed with
hERG1aUSO-G628S at ratios approximating those found in the
heart. (A) Representative current traces recorded from Flp-Cre cells
expressing hERG1a (1a) from the weak SV40 promoter (pSV40) at the
FRT site and empty vector, hERG1a-G628S (1a-Mut), or hERG1aUSOG628S (1aUSO-Mut) from the CMV promoter (pCMV) at the loxP2272/loxP
site. The patch-clamp protocol is given in the legend of Fig. 2. (B)
Averaged tail current amplitude measured at 250 mV following
depolarizing voltages from 30 mV. The number of cells is shown in
parentheses.
doi:10.1371/journal.pone.0042552.g008

Figure 7. Co-assembly of hERG1 isoforms expressed at ratios
approximating those found in the heart. (A) Proteins from Flp-Cre
cells expressing HA-tagged hERG1a (1a) from the weak SV40 promoter
(pSV40) at the FRT site and Flag-tagged hERG1a-G628S (1a-Mut) or
hERG1aUSO-G628S (1aUSO-Mut) from the CMV promoter (pCMV) at the
loxP2272/loxP site were detected by western blot with the anti-HA (upper
panel) and the anti-Flag antibody (middle panel). Flp-Cre cells expressing
HA-tagged hERG1a from the CMV or SV40 promoter at the FRT site and
empty vector in loxP2272/loxP site were used as controls; tubulin was used
as a loading control (lower panel). (B) Co-assembly of hERG1 isoforms was
determined by immunoprecipitation using the anti-HA antibody followed
by western blot with the anti-Flag and the anti-HA antibody. Results
shown are representative of three independent experiments.
doi:10.1371/journal.pone.0042552.g007

FRT site and the loxP2272/loxP sites allowing Flp recombinasemediated recombination and Cre recombinase-mediated cassette
exchange reactions, respectively. Flp-Cre cells were cultured in
DMEM and 10% fetal bovine serum and 1 mg/ml puromycin.
The pUC18/loxP expression vector (Fig. 1B) was designed to
stably integrate a gene of interest at the loxP2272/loxP site of FlpCre cells. The vector contains loxP2272 and loxP sites flanking the
neomycin resistance gene and the gene of interest. The expression
of the gene of interest was controlled by the CMV promoter. The
promoter controlling the expression of the neomycin resistance
gene is provided only upon recombination within the loxP2272/
loxP cassette in the Flp-Cre cells. Stable integration of the gene of
interest was achieved by co-transfecting Flp-Cre cells with the
pUC18/loxP vector (0.1 mg) containing the gene of interest and a
Cre recombinase expression vector (pBS185, 0.9 mg) [37] using the
Effectene method. Forty-eight hours post-transfection, the cells
were cultured in DMEM and 10% FBS and 400 mg/ml G418.
To generate double-stable cell lines, HA-tagged hERG1a was
stably integrated at the FRT site of Flp-Cre cells by co-transfection
with the pcDNA5/FRT expression vector containing hERG1aHA (0.1 mg) and the Flp recombinase expression vector pOG44
(0.9 mg) using the Effectene method and selected with 100 mg/ml

derived from pUC18 (Fermentas, Glen Burnie, MD) and contains
a loxP2272/loxP recombination cassette comprised of incompatible
loxP2272 and loxP sites flanking the puromycin resistance gene and
green fluorescence protein (GFP) (Fig. 1A). The 8 nt spacer region
of the loxP2272 and loxP sites differ by 2 nt precluding crossrecombination reactions [36]. Expression of the puromycin
resistance gene is controlled by the PGK promoter inserted
directly upstream of the loxP2272 site, outside of the loxP2272/loxP
cassette. The expression of GFP is controlled by the CMV
promoter. Flp-In-293 cells were transfected with the pCRE/GFP
vector (1.0 mg) using the Effectene method (Qiagen, Valencia,
CA). Forty-eight hours post-transfection, the cells were cultured in
DMEM and 10% FBS and 1 mg/ml puromycin. After fifteen days,
single colonies stably expressing GFP were selected with cloning
cylinders. Quantitative real-time PCR was performed to confirm
the integration of a single copy of the loxP2272/loxP cassette. The
resultant stable host cell line, Flp-Cre, contains a single copy of the
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hygromycin (Fig. 1C). Flag-tagged wild-type and mutant hERG1
isoforms were then stably integrated at the loxP2272/loxP site of
cells stably expressing hERG1a-HA using the Cre recombinasemediated recombination approach described above (Fig. 1D). The
promoters controlling the expression of the hygromycin and
neomycin resistance genes are provided only upon recombination
at the FRT and loxP2272/loxP sites, respectively. This ensures that
each cell contains a single copy of the HA-tagged and Flag-tagged
hERG1 genes (Fig. 1E), and allows the polyclonal selection of the
double-stable cell line.

component of the pUC18/loxP expression vector and is stably
integrated at the loxP2272/loxP site of Flp-Cre cells. The
polyclonal anti-neomycin phosphotransferase II antibody (Milipore, Billerica, MA) was used at a 1:300 dilution. In the
immunoprecipitation experiments, cells were lysed with immunoprecipitation buffer (10 mM Tris-HCl, pH 8.0, 150 mM NaCl,
5 mM EDTA, 1% Triton X-100, 1 mg/ml BSA and protease
inhibitors), hERG1 channels were immunoprecipitated with the
anti-HA antibody and detected by western blot with the anti-Flag
and the anti-HA antibody. hERG1 protein was quantified by
densitometry with ImageJ software [40].

Quantitative PCR
Quantitative real-time PCR was used to confirm the copy
number of the FRT and loxP2272/loxP target sites within the FlpCre cell line. Genomic DNA from Flp-Cre clone #14 was isolated
with the Gentra Puregene kit (Qiagen) following the manufacturer’s protocol. PCR primers were specific to sequences within the
FRT (zeocin resistance gene) and loxP2272/loxP (GFP) cassette.
Primer sequences are: zeocin forward (59-GTT GAC CAG TGC
CGT TCC-39), zeocin reverse (59-TGA ACA GGG TCA CGT
CGT C-39), GFP forward (59-GCG AGG GCG ATG CCA CCT
AC-39), and GFP reverse (59-TCG GGG TAG CGG CTG AAG
CA-39). To take into account the amplification efficiency of each
primer set, we used a plasmid DNA containing the cDNAs of
zeocin and GFP as template for generating standard curves for
each primer set. By using a plasmid in which the zeocin and GFP
cDNA fragments are at 1:1 ratio, equal quantities can be assigned
to each dilution point of the standard curves [38]. PCR was
performed on the MX300P real-time PCR machine (Stratagene,
La Jolla, CA) using Power SYBR Green PCR Master Mix
(Applied Biosystems, Foster City, CA). After denaturing at 95uC
for 10 min, the reaction was run for 40 cycles with denaturation at
95uC for 30 s, annealing at 55uC for 30 s and primer extension at
72uC for 30 s.

Immunofluorescence microscopy
The characterization of wild-type and mutant hERG1 channel
trafficking by immunofluorescence has been described previously
[41]. Briefly, Flp-Cre cell lines stably expressing HA-tagged
hERG1a and Flag-tagged hERG1a or Flag-tagged hERG1aUSO
channels were fixed with 4% paraformaldehyde, blocked with PBS
containing 5% goat serum and 0.2% Triton X-100, and incubated
with monoclonal anti-HA and polyclonal anti-Flag antibody for
one hour at room temperature. The cells were then washed and
probed with Alexa Fluor 488-conjugated goat anti-mouse and
Alexa Fluor 594-conjugated goat anti-rabbit secondary antibody
(Molecular Probes, Eugene, OR). Images were acquired with a
Zeiss Axioskop 2 microscope.

Supporting Information
Figure S1 Flp-Cre cells co-expressing HA-tagged hERG1a (1a)
and Flag-tagged wild-type (WT) or mutant (Mut) 1a or
hERG1aUSO (1aUSO) channels were lysed using an immunoprecipitation buffer containing the NP40 detergent. hERG1 channels
were detected by western blot with the anti-HA and the anti-Flag
antibody (upper two panels). Co-assembly of hERG1 isoforms was
determined by immunoprecipitation with the anti-HA antibody
and detection with the anti-Flag and the anti-HA antibody (lower
three panels). Results shown are representative of three independent experiments.
(TIF)

Electrophysiology
Membrane currents were recorded in whole cell configuration
using suction pipettes, at ,22uC, as previously described [11]. An
Axopatch-200B amplifier was used to record membrane currents
and the computer software pCLAMP8 was used to analyze current
signals. Data are presented as mean 6 SEM and analyzed by
Student’s t-test. P,0.05 is considered statistically significant.

Immunofluorescence staining of Flp-Cre cells stably
expressing HA-tagged hERG1a and Flag-tagged hERG1a-G628S
or Flag-tagged hERG1aUSO-G628S channels. The phase contrast
image, the monoclonal anti-HA staining, the polyclonal anti-Flag
staining and the merged fluorescence signal from the anti-HA and
anti-Flag staining are shown. Bar 20 mm, applies to all panels.
(TIF)
Figure S2

Western blot and immunoprecipitation
Western blot analysis and immunoprecipitation were performed
as previously described [31,39]. Briefly, proteins from whole cell
lysates were subjected to SDS-PAGE, transferred onto nitrocellulose membranes, detected with the anti-HA and the anti-Flag
antibody and visualized with the Plus-ECL (PerkinElmer, Waltham, MA) detection kit. The expression level of neomycin
phosphotransferase II encoded by the neomycin resistant gene was
used as an internal control for normalizing the relative expression
of hERG isoform proteins. The neomycin resistance gene is a
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